Journal
LEUKEMIA
Volume 23, Issue 6, Pages 1062-1072Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2008.399
Keywords
chronic lymphocytic leukemia; telomere; prognosis; Richter's syndrome; kinetics
Categories
Funding
- Compagnia di San Paolo (Torino, Italy)
- Ministero Italiano Universitae Ricerca (MIUR)
- Fondazione Neoplasie del sangue
Ask authors/readers for more resources
Telomere length (TL) has been associated with outcome in chronic lymphocytic leukemia (CLL). The aim of this extensive analysis carried out on 401 CLL patients was to assess TL conclusively as a prognostic biomarker. Our study included two cohorts used as learning (191 patients) and blinded validation series (210 patients). A TL cutoff of 5000 bp was chosen by receiver operating characteristic (ROC) analysis and Youden's index in the learning series. In this series, TL <= 5000 bp was independently associated to a worse outcome for both overall survival (OS; 105.5 vs 281 months, P<0.001) and treatment-free survival (TFS; 24.6 vs 73 months, P<0.001). In the blinded validation series, TL <= 5000 bp was confirmed as an independent outcome predictor for OS (79.8 vs not reached, P<0.001) and TFS (15.2 vs 130.8 months, P<0.001). Moreover, TL <= 5000 bp independently predicted the risk of Richter's syndrome (5-year risk: 18.9 vs 6.4%, P = 0.016). Within CLL subsets defined by biological predictors, TL consistently identified patient subgroups harboring unfavorable prognosis. These results demonstrate that TL is a powerful independent predictor of multiple outcomes in CLL, and contributes to refine the prognostic assessment of this disease when utilized in combination with other prognostic markers. We thus believe that this prognostic biomarker has the potential for a more widespread use in CLL. Leukemia (2009) 23, 1062-1072; doi: 10.1038/leu.2008.399; published online 2 April 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available